134A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy.

Trial Profile

134A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Tacrolimus (Primary) ; Basiliximab; Methylprednisolone; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SALAMI
  • Most Recent Events

    • 19 Sep 2013 Results published in Transplantation.
    • 22 May 2013 Results at 3 years presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 04 May 2011 Results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top